You are viewing the site in preview mode

Skip to main content

Advertisement

Figure 2 | BMC Infectious Diseases

Figure 2

From: Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: Derivation of a clinical algorithm

Figure 2

Observed and expected adverse events (A) and mortality (B) within CURB65 class 0/1 (low risk patients). Observed and expected adverse events and mortality within CURB65 class 0/1 (low risk patients). A. Calibration of initial ProADM deciles and adverse events. B. Calibration of ProADM deciles and mortality.

Back to article page